**Findings** 

nodule(s) with specific calcifications: complete, central, popcorn, concentric

prior chest CT examination(s) being located for comparison

< 6 mm total diameter on baseline screening

≥ 20 mm and unchanged or slowly growing category 3 or 4 nodules unchanged for ≥ 3 months

part or all of lungs cannot be evaluated

rings and fat containing nodules

no lung nodules

solid nodule(s): < 6 mm new < 4 mm

part solid nodule(s):

non solid nodule(s) (GGN):

< 20 mm OR

Category

Incomplete

Negative

Benign

Appearance

or Behavior

**Category Descriptor** 

No nodules and

definitely benign

nodules

Nodules with a very low

likelihood of becoming a

clinically active cancer due

to size or lack of growth

4) Growth: an increase in size of > 1.5 mm

\*Link to McWilliams Lung Cancer Risk Calculator

making recommendations

13) LDCT: low dose chest CT

6) Exam Modifiers: S and C modifiers may be added to the 0-4 category

Upon request from the authors at: http://www.brocku.ca/lung-cancer-risk-calculator

5) Exam Category: each exam should be coded 0-4 based on the nodule(s) with the highest degree of suspicion

8) Practice audit definitions: a negative screen is defined as categories 1 and 2; a positive screen is defined as categories 3 and 4

11) Nodules with features of an intrapulmonary lymph node should be managed by mean diameter and the 0-4 numerical category classification 12) Category 3 and 4A nodules that are unchanged on interval CT should be coded as category 2, and individuals returned to screening in 12 months

At UptoDate http://www.uptodate.com/contents/calculator-solitary-pulmonary-nodule-malignancy-risk-brock-university-cancer-prediction-equation

Category

2

Estimated

Population

Prevalence

1%

90%

Probability of

Malignancy

n/a

< 1%

Management

Additional lung cancer screening CT images and/or

comparison to prior chest CT examinations is needed

Continue annual screening with

LDCT in 12 months

Probably Benign	Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer	3	solid nodule(s):  ≥ 6 to < 8 mm at baseline OR  new 4 mm to < 6 mm  part solid nodule(s)  ≥ 6 mm total diameter with solid component < 6 mm OR  new < 6 mm total diameter  non solid nodule(s) (GGN) ≥ 20 mm on baseline CT or new	6 month LDCT	1-2%	5%
Suspicious	Findings for which additional diagnostic testing and/or tissue	4A	solid nodule(s):  ≥ 8 to < 15 mm at baseline OR growing < 8 mm OR new 6 to < 8 mm part solid nodule(s:  ≥ 6 mm with solid component ≥ 6 mm to < 8 mm OR with a new or growing < 4 mm solid component endobronchial nodule	3 month LDCT; PET/CT may be used when there is a ≥ 8 mm solid component	5-15%	2%
	sampling is recommended	4B 4X	solid nodule(s)  ≥ 15 mm OR  new or growing, and ≥ 8 mm  part solid nodule(s) with:  a solid component ≥ 8 mm OR  a new or growing ≥ 4 mm solid component  Category 3 or 4 nodules with additional features or imaging findings that increases the suspicion of malignancy	chest CT with or without contrast, PET/CT and/or tissue sampling depending on the *probability of malignancy and comorbidities. PET/CT may be used when there is a ≥ 8 mm solid component.	> 15%	2%
Other	Clinically Significant or Potentially Clinically Significant Findings (non lung cancer)	S	modifier - may add on to category 0-4 coding	As appropriate to the specific finding	n/a	10%
Prior Lung Cancer	Modifier for patients with a prior diagnosis of lung cancer who return to screening	С	modifier - may add on to category 0-4 coding		-	-
IMPORTANT NOTES FOR USE:  1) Negative screen: does not mean that an individual does not have lung cancer  2) Size: nodules should be measured on lung windows and reported as the average diameter rounded to the nearest whole number; for round nodules only a single diameter measurement is necessary  3) Size Thresholds: apply to nodules at first detection, and that grow and reach a higher size category						

7) Lung Cancer Diagnosis: Once a patient is diagnosed with lung cancer, further management (including additional imaging such as PET/CT) may be performed for purposes of lung cancer staging; this is no longer screening

10) Category 4X: nodules with additional imaging findings that increase the suspicion of lung cancer, such as spiculation, GGN that doubles in size in 1 year, enlarged lymph nodes etc

9) Category 4B Management: this is predicated on the probability of malignancy based on patient evaluation, patient preference and risk of malignancy; radiologists are encouraged to use the McWilliams et al assessment tool when